Stephen Ahenkorah -

View Scopus Profile

Research activity per year

7 In-proceedings paper
6 Article
1 Literature review
1 Doctoral thesis

Effectiveness of [⁶⁷Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer
Pougoue Ketchemen, J., Njotu, F. N., Babeker, H., Ahenkorah, S., Tikum, A. F., Nwangele, E., Henning, N., Cleeren, F. & Fonge, H., Jun 2024, In: European Journal of Nuclear Medicine and Molecular Imaging. 51, 7, p. 2070–2084 15 p.
Research output › peer-review

Open Access
3p-C-NETA-TATE: a theranostic somatostatin analogue targeting neuroendocrine tumors
Ahenkorah, S., Murce, E., Cawthorne, C., Seimbille, Y., Cardinaels, T., Deroose, C., Bormans, G., Ooms, M. & Cleeren, F., 15 Jun 2023, Abstracts from the 20th European symposium on radiopharmacy and radiopharmaceuticals. 1 ed. Springer, Vol. 8. p. 6-6 1 p. OP13. (EJNMMI Radiopharmacy and Chemistry ; vol. 8, no. Supplement 1).
Research output › peer-review

Open Access
Direct comparison of [18F]AlF-NOTA-JR11 and [18F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist
Ahenkorah, S., Cawthorne, C., Murce, E., Deroose, C., Cardinaels, T., Seimbille, Y., Bomans, G., Ooms, M. & Cleeren, F., 1 Mar 2023, In: Nuclear Medicine and Biology. 118-119, 10 p., 108338.
Research output › peer-review

Open Access
Radiochemical and Biological Evaluation of 3p-C-NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics
Murce, E., Ahenkorah, S., Beekman, S., Handula, M., Stuurman, D., de Ridder, C., Cleeren, F. & Seimbille, Y., Jun 2023, In: Pharmaceuticals. 16, 6, 18 p., 882.
Research output › peer-review

Open Access
3p-C-NETA: A versatile and effective chelator for development of Al¹⁸F-labeled and therapeutic radiopharmaceuticals
Ahenkorah, S., Murce, E., Cawthorne, C., Ketchemen, J. P., Deroose, C. M., Cardinaels, T., Seimbille, Y., Fonge, H., Gsell, W., Bormans, G., Ooms, M. & Cleeren, F., 2022, In: Theranostics. 12, 13, p. 5971-5985 15 p.
Research output › peer-review

Open Access

7 Scopus citations

Stephen Ahenkorah

Collaborations and top research areas from the last five years

Dive into details

Effectiveness of [⁶⁷Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer

3p-C-NETA-TATE: a theranostic somatostatin analogue targeting neuroendocrine tumors

Direct comparison of [18F]AlF-NOTA-JR11 and [18F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist

Radiochemical and Biological Evaluation of 3p-C-NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics

3p-C-NETA: A versatile and effective chelator for development of Al¹⁸F-labeled and therapeutic radiopharmaceuticals

Stephen Ahenkorah

Collaborations and top research areas from the last five years

Research output

Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer

3p-C-NETA-TATE: a theranostic somatostatin analogue targeting neuroendocrine tumors

Direct comparison of [18F]AlF-NOTA-JR11 and [18F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist

Radiochemical and Biological Evaluation of 3p-C-NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics

3p-C-NETA: A versatile and effective chelator for development of Al18F-labeled and therapeutic radiopharmaceuticals

Effectiveness of [⁶⁷Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer

3p-C-NETA: A versatile and effective chelator for development of Al¹⁸F-labeled and therapeutic radiopharmaceuticals